{"id":"W4322771875","doi":"10.1158/1538-7445.sabcs22-ot2-16-05","title":"Abstract OT2-16-05: Safety Analyses of NRG BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-Positive Metastatic Breast Cancer (MBC)","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pertuzumab; Taxane; Metastatic breast cancer; Atezolizumab; Internal medicine; Oncology; Clinical endpoint; Placebo; Trastuzumab; Randomized controlled trial; Breast cancer; Ixabepilone; Interim analysis; Surgery; Cancer; Nivolumab; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005888969,0.001836693,0.002134508,0.0005649956,0.0004455831,0.001157674,0.00127717,0.001893544,0.01550725],"category_scores_gemma":[0.004381486,0.0006082359,0.002279772,0.0004978366,0.001414297,0.0007976427,0.0004011673,0.003140873,0.001577149],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001046238,"about_ca_system_score_gemma":0.002722084,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006884355,"about_ca_topic_score_gemma":0.001313281,"domain_scores_codex":[0.9974361,0.001890632,0.0001165031,0.0002156457,0.0001937495,0.0001474761],"domain_scores_gemma":[0.9972203,0.0007691658,0.0008422523,0.0002751072,0.0002372932,0.0006558889],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9789141,0.005877283,0.0004714605,0.0003746314,0.00053562,0.00003682298,0.00002513752,0.0002238089,0.003856731,0.0001194842,0.001308845,0.00825609],"study_design_scores_gemma":[0.9201723,0.07634703,0.00113534,0.00002252488,0.0003894413,0.00002468948,0.000007048368,0.0002629594,0.0007664905,0.0001207697,0.0007425969,0.000008861854],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9647531,0.002915218,0.002820191,0.0009818038,0.0006566372,0.0162901,0.005886016,0.0004871581,0.005209676],"genre_scores_gemma":[0.9615908,0.001355017,0.004986792,0.001657527,0.0007605411,0.0157518,0.005093496,0.00009728791,0.008706722],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01550725,"threshold_uncertainty_score":0.0518769,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1641459642196728,"score_gpt":0.485260842463795,"score_spread":0.3211148782441222,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}